@article{50afc8b564a94e2cbc06f668d5d5b98d,
title = "Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects",
abstract = "COPD, chronic bronchitis (CB) and active smoking have all been associated with goblet cell hyperplasia (GCH) in small studies. Active smoking is strongly associated with CB, but there is a disconnect between CB clinical symptoms and pathology. Chronic cough and sputum production poorly correlate with the presence of GCH or COPD. We hypothesized that the primary determinant of GCH in ever smokers with or without airflow obstruction is active smoking. Goblet Cell Density (GCD) was measured in 71 current or former smokers [32 subjects without COPD and 39 COPD subjects]. Endobronchial mucosal biopsies were stained with Periodic Acid Schiff-Alcian Blue, and GCD was measured as number of goblet cells/mm basement membrane. GCD was divided into tertiles based on log10 transformed values. Log10GCD was greater in current smokers compared to former smokers. Those with classically defined CB or SGRQ defined CB had a greater log10 GCD compared to those without CB. Current smoking was independently associated with tertile 3 (high log10GCD) whereas CB was not in multivariable regression when adjusting for lung function and demographics. These results suggest that GCH is induced by active smoke exposure and does not necessarily correlate with the clinical symptoms of CB.",
author = "Victor Kim and Stephanie Jeong and Huaqing Zhao and Mehmet Kesimer and Boucher, {Richard C.} and Wells, {J. Michael} and Christenson, {Stephanie A.} and Han, {Mei Lan K.} and Mark Dransfield and Robert Paine and Cooper, {Christopher B.} and Igor Barjaktarevic and Russell Bowler and Curtis, {Jeffrey L.} and Kaner, {Robert J.} and O{\textquoteright}Beirne, {Sarah L.} and O{\textquoteright}Neal, {Wanda K.} and Rennard, {Stephen I.} and Martinez, {Fernando J.} and Woodruff, {Prescott G.}",
note = "Funding Information: In the past three years, Victor Kim has received personal fees from Gala Therapeutics, AstraZeneca, and Boehringer Ingelheim outside of the submitted work. Jeffrey L. Curtis reports a grant from NIH/NHLBI during the conduct of this study; grants from NIH/NHBLI, NIH/NIAID, the Department of Veterans Affairs, and the Department of Defense outside the submitted work; and personal fees from AstraZeneca outside the submitted work. Stephanie Jeong, Huaqing Zhao, Mehmet Kesimer, Richard C. Boucher, Stephanie A. Christenson, Meilan K. Han, Mark Dransfield, Robert Paine III, Christopher B. Cooper, Igor Barjaktarevic, Russell Bowler, Robert J. Kaner, Sara L. O{\textquoteright}Beirne, Wanda K. O{\textquoteright}Neal, and Fernando J. Martinez report no conflicts of interest. J. Michael Wells reports grants from NIH/NHLBI, during the conduct of the study; grants from NIH/NCATS, grants from Bayer, grants and other from GSK, other from Boehringer Ingelheim, grants and other from Mereo BioPharma, other from ICON, other from PRA, other from Vertex Pharmaceuticals, outside the submitted work. Stephen I. Rennard was employed by AstraZeneca until November, 2019 and has consulted for GSK and BerGenBio. Prescott G Woodruff reports personal fees from Glaxosmithkline, personal fees from NGM biopharmaceuti-cals, personal fees from Amgen, personal fees from Glenmark Pharmaceuticals, personal fees from Theravance, personal fees from Clarus Ventures, personal fees from Astra Zeneca, personal fees from 23andMe, personal fees from Sanofi, personal fees from Regeneron, personal fees from Genentech, outside the submitted work. Funding Information: SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), Grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan. Publisher Copyright: {\textcopyright} 2020, The Author(s).",
year = "2020",
month = dec,
doi = "10.1038/s41598-020-77229-1",
language = "English (US)",
volume = "10",
journal = "Scientific reports",
issn = "2045-2322",
publisher = "Nature Research",
number = "1",
}